A Randomized, Double-Blind, Placebo-Controlled Pilot Study of

Status Completed

Clinical Trial Summary

The purpose of this study is to explore the safety and efficacy of a sublingual (under the tongue) immunotherapy (SLIT) dosing regimen and an oral immunotherapy (OIT) regimen in inducing desensitization and long term tolerance in children with persistent peanut allergy.

Clinical Trial Description

To effectively address the Primary Objectives of this pilot study, 30 subjects aged 6-21 years with: (1) a convincing clinical history of PA, (2) a serum IgE specific to peanut of >0.35 kUa/L and a skin prick test (SPT) wheal >3 mm, will be enrolled. Subjects will be recruited from the Johns Hopkins Pediatric Allergy Clinic.

Participants will undergo an initial screening visit that will include a medical history, physical exam, skin testing, and phlebotomy. Informed consent and assent will be obtained. At the next two visits, 20 participants will complete a double-blind placebo-controlled food challenge (DBPCFC). Eligible subjects will be randomized in a 1:1 ratio into two groups. One group will receive active SLIT with placebo OIT and the other group will begin active OIT with placebo SLIT dose escalation. Over the next 16 weeks of the study, subjects will undergo SLIT and OIT dose increases. A maintenance dose will then be taken at home daily for 12 months. A DBPCFC will be completed after 6 months and 12 months of home dosing. Those patients who pass the DBPCFC will be taken off SLIT and OIT for 4 weeks. A final challenge will be administered at the end of this period.

Ten additional peanut-allergic subjects age 6-21 years will be enrolled and followed as longitudinal controls for the mechanistic studies. These subjects will follow a modified schedule compared to those subjects receiving study treatment and will be evaluated by phlebotomy, end point titration prick skin testing, and saliva collection. These patients will continue strict avoidance of peanut unless otherwise advised by their personal physician. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01084174
Study type	Interventional
Source	Johns Hopkins University
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	March 2010
Completion date	January 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01904604` - Peanut Epicutaneous Phase II Immunotherapy Clinical Trial	Phase 2
Enrolling by invitation	`NCT04885959` - The Effects of Traditional Asian Diet on Gut Microbiome and Metabolome in Healthy Volunteers and Pregnancy on Subsequent Infant's Allergy Development	N/A
Recruiting	`NCT03974555` - Epidemiological Investigation and Cohort Study on Food Allergy in Children Aged 3 to 6 Years in Wenzhou and Taizhou Urban Areas
Recruiting	`NCT05177744` - Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
Completed	`NCT01420705` - Bacille Calmette-Guérin (BCG) Vaccine and Atopy	N/A
Completed	`NCT00850668` - Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults	Phase 1
Withdrawn	`NCT00736112` - Food Allergy - Tubes - Adenoids (FATA) Trial	N/A
Active, not recruiting	`NCT00298337` - Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008	Phase 2/Phase 3
Completed	`NCT03693456` - Food Allergy Diagnostic Test Response to Previous Oral Challenge Response	N/A
Completed	`NCT00461097` - Oral Immunotherapy for Childhood Egg Allergy	Phase 2
Completed	`NCT02606721` - Food Allergy Challenge Diagnostic Study
Active, not recruiting	`NCT02457416` - Take Away Food Allergy; Inducing Tolerance in Children Allergic to Peanut	N/A
Completed	`NCT02825069` - Study on the Induction of Food Tolerance in Babies	N/A
Completed	`NCT02350660` - Oral Immunotherapy for Peanut and Mammalian Meat Allergies	N/A
Completed	`NCT00597675` - Oral Immunotherapy for Peanut Allergy (PMIT)	Phase 2
Completed	`NCT00932828` - Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study	Phase 2
Completed	`NCT01373242` - Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance	Phase 1/Phase 2
Completed	`NCT00578656` - An Interventional Study of Milk Allergy	Phase 0
Completed	`NCT00356174` - An Observational Study of Childhood Food Allergy	N/A
Completed	`NCT03639337` - Colonization and Persistence Capacity of a Multi-strain Probiotics in Pediatric Food Allergy to Milk or Egg.	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms